Article
Biochemistry & Molecular Biology
Yifan Zhang, Yi Chen, Andri Papakonstantinou, Panagiotis Tsagkozis, Christina Linder-Stragliotto, Felix Haglund
Summary: This study investigated the PD-L1 immunoreactivity in high-grade chondrosarcomas, abdominal liposarcoma, and undifferentiated pleomorphic sarcomas. It found that the majority of tumors exhibited low PD-L1 immunoreactivity, but a subset showed high immunoreactivity. However, there was no significant difference in metastasis-free or overall survival in relation to PD-L1 immunoreactivity in any subtype.
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Article
Oncology
LeAnne Young, Shanda Finnigan, Howard Streicher, Helen X. Chen, James Murray, H. Nida Sen, Elad Sharon
Summary: Ocular adverse events are rare complications of PD-1/PD-L1 inhibitor therapy, but can be severe enough to cause treatment discontinuation or delay. Proper evaluation by eye specialists is necessary in managing these adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Meghan M. Lynch, Borislav A. Alexiev, Brett A. Schroeder, Seth M. Pollack
Summary: Although no PD-1 inhibitor has been FDA approved for use in sarcoma, the use of single agent PD-1 inhibitors is considered standard-of-care in certain specific subtypes and situations. While the role of immunotherapy in sarcoma is still being defined, there is increasing interest in combining PD-1 inhibitors with standard treatments, especially chemotherapy, with early phase trials showing potential benefits. More data is needed to support the combination of PD-1 inhibitors and chemotherapy, and further evaluation in well-designed clinical trials is recommended.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh
Summary: Using protease-activatable antibody prodrugs (Pb-Tx) to locally inhibit PD-1/PD-L1 can reduce systemic immune toxicity while eliciting potent anti-tumor immune responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Laurene S. Cheung, Lingling Chen, Teniola F. Oke, Thomas B. Schaffer, Karim Boudadi, Jillian T. Ngo, John McMahon Gross, Holly Kemberling, Luis A. Diaz, Evan Lipson, John-William Sidhom, Janis Taube, Robert Anders, Drew M. Pardoll, Dung T. Le, Christian F. Meyer, Nicolas Llosa
Summary: Head and neck UPS tumors, characterized by high TMB, increased PD-L1 expression, and CD8+ T cell infiltration, represent a distinct genetic subgroup for which immune checkpoint inhibitor therapy might be effective.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Jinhua Liu, Zichao Chen, Yaqun Li, Wenjie Zhao, JiBiao Wu, Zhen Zhang
Summary: Programmed death protein 1 (PD1) is an important immune checkpoint on T cells that plays a crucial role in downregulating the immune system and promoting self-tolerance, while its ligand, programmed cell death ligand 1 (PDL1), is overexpressed in malignant tumor cells, contributing to immune evasion and treatment failure. Despite the clinical efficacy of PD1/PDL1 inhibitors in many tumors, some patients may develop drug resistance, highlighting the need for further research into improving targeted therapies and understanding the associated safety issues.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Mengke Niu, Yiming Liu, Ming Yi, Dechao Jiao, Kongming Wu
Summary: The immune checkpoint pathway involving PD-1 and PD-L1 plays a crucial role in inhibiting T-cell proliferation and function, affecting antitumor immune responses. Alternative forms of PD-1/PD-L1, such as sPD-1/sPD-L1 and exoPD-L1, have been detected in cancer patients and may have significant biological activities.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medical Laboratory Technology
Yamin Liang, Lu Li, Yanmei Chen, Jinyan Xiao, Dangheng Wei
Summary: The PD-1/PD-L1 pathway is crucial in immune responses and cancer therapy, but may accelerate the progression of atherosclerosis in some patients.
CLINICA CHIMICA ACTA
(2021)
Review
Biochemistry & Molecular Biology
Enrico Munari, Francesca R. Mariotti, Linda Quatrini, Pietro Bertoglio, Nicola Tumino, Paola Vacca, Albino Eccher, Francesco Ciompi, Matteo Brunelli, Guido Martignoni, Giuseppe Bogina, Lorenzo Moretta
Summary: Immune evasion is a crucial strategy adopted by tumor cells to promote survival and metastasis, with PD-1 playing a major role in inhibiting immune responses. Targeting the PD-1/PD-L1 axis has been a significant breakthrough in cancer treatment, representing unprecedented success in various cancer types. Further research on mechanisms regulating PD-1 expression and signaling in tumors is needed to improve therapeutic efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Li Liu, Long Liang, Hui Li, Wenjun Shao, Chaoying Yang, Feng Lin, Jing Liu, Ji Zhang
Summary: N6-methyladenosine (m6A) is an important posttranscriptional RNA modification in eukaryotic cells and its involvement in antitumor immunity has been recognized. The interaction between PD-L1 and PD-1 plays a crucial role in inhibiting tumor responses, and targeting this interaction has shown promise in immunotherapy. However, resistance to these tools remains a challenge. Understanding the role of m6A in RNA biogenesis and drug resistance can aid in personalized clinical management. This review explores the mechanisms by which m6A regulates PD-1 and PD-L1 expression, its impact on tumor immunotherapy, and the potential application of m6A-associated molecules. Additionally, the use of m6Ascore to evaluate cancer prognosis is discussed.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Oncology
Valentin Vautrot, Hafidha Bentayeb, Sebastien Causse, Carmen Garrido, Jessica Gobbo
Summary: Immunotherapy, particularly through the blockade of immune checkpoints such as PD-1/PD-L1, has become increasingly important in cancer treatment by reactivating the immune system to fight cancer cells. However, resistance to these treatments in a certain proportion of patients has led to efforts to combine PD-1/PD-L1 immunotherapy with targeting other immune checkpoints to improve outcomes. Exosomes, small vesicles secreted by various cells including tumor cells, play a key role in mediating immune resistance and establishing metastatic niches. Research on specific exosomal proteins like PD-L1, CTLA-4, TIM-3, CD73/39, LAG-3, and TIGIT aims to enhance understanding of tumor resistance mechanisms and guide therapeutic decisions in immunotherapy.
Review
Oncology
Mengling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang, Yong Xia
Summary: PD-1/PD-L1 immune checkpoints inhibit the anticancer effect of T cells in the tumor microenvironment, and downregulation or upregulation of PD-L1 expression can improve the efficacy of anti-PD-1/PD-L1 treatment. Overcoming the current limitations of this treatment can expand its anticancer applications and improve patient response rates and survival time.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Laure Chardin, Alexandra Leary
Summary: Ovarian cancer is a highly lethal gynecologic malignancy with a high recurrence rate, despite many patients responding effectively to current treatments. In order to improve outcomes, further research into the immune microenvironment and the development of effective therapies are urgently needed.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Erkan Kozanoglu, Neslihan Gokcen, Sibel Basaran, Semra Paydas
Summary: This study investigates the long-term effectiveness of combined IPC plus LLLT versus IPC therapy alone in patients with postmastectomy upper limb lymphedema. The results show that both interventions have positive effects on lymphedema, grip strength, and pain, with the combined therapy showing slightly superior long-term effects on pain compared to pneumatic compression alone.
LYMPHATIC RESEARCH AND BIOLOGY
(2022)
Article
Oncology
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Ozgur Acikgoz, Ahmet Sezer, Mustafa Gurbuz, Naziye Ak, Sebnem Yucel, Murat Ayhan, Cihan Erol, Aykut Demirkiran, Nil Molinas Mandel, Abdallah Shbair, Ivo Gokmen, Tugba Basoglu, Semra Paydas, Atike Gokcen Demiray, Yakup Iriagac, Teoman Sakalar, Esra Zeynelgil, Ali Murat Tatli, Aykut Bahceci, Deniz Can Guven, Burcu Caner, Alper Can, Ahmet Gulmez, Yusuf Karakas, Bulent Yalcin, Ahmet Demirkazik, Ahmet Bilici, Adnan Aydiner, Perran Fulden Yumuk, Mehmet Ali Nahit Sendur
Summary: This study showed that Osimertinib is a highly effective and safe option for NSCLC patients with T790M mutation in second- or third-line treatment. The median time-to-treatment discontinuation (TTD) was 21.6 months, with an objective response rate of 82.2% and a median overall survival of 32.1 months.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, Semih Akin, Fatih Yildiz, Merve Turan, Sema Sezgin Goksu, Ismail Beypinar, Teoman Sakalar, Mustafa Degirmenci, Dilek Erdem, Gul Basaran, Omer Fatih Olmez, Nilufer Avci, Deniz Tural, Abdullah Sakin, Sema Turker, Atakan Demir, Suleyman Temiz, Muhammed Ali Kaplan, Mutlu Dogan, Ozgur Tanriverdi, Irem Bilgetekin, Havva Yesil Cinkir, Ozgur Acikgoz, Semra Paydas, Ruchan Uslu, Serdar Turhal
Summary: The study evaluated the efficacy and safety of everolimus plus exemestane in HR+/HER2- MBC patients, showing favorable outcomes in terms of response rate, progression-free survival, and overall survival.
CANCER INVESTIGATION
(2022)
Article
Hematology
Eren Gunduz, Hakki Onur Kirkizlar, Elif Gulsum Umit, Sedanur Karaman Gulsaran, Vildan Ozkocaman, Fahir Ozkalemkas, Omer Candar, Tugrul Elverdi, Selin Kucukyurt, Semra Paydas, Ozcan Ceneli, Sema Karakus, Senem Maral, Omer Ekinci, Yildiz Ipek, Cem Kis, Zeynep Tugba Guven, Aydan Akdeniz, Tiraje Celkan, Ayse Hilal Eroglu Kucukdiler, Gulsum Akgun Cagliyan, Ceyda Ozcelik Sengoz, Ayse Karatas, Tuba Bulduk, Alper Ozcan, Fatma Burcu Belen Apak, Aylin Canbolat, Ibrahim Kartal, Hale Oren, Ersin Toret, Gul Nihal Ozdemir, Sule Mine Bakanay Ozturk
Summary: This study presents patient characteristics and treatment strategies for Castleman disease from Turkey, contributing to increased awareness about the disease. Larger prospective studies are needed for definitive conclusions.
TURKISH JOURNAL OF HEMATOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Umur Anil Pehlivan, Kadir Oktay, Hasan Bilen Onan, Arbil Acikalin, Celalet Keser, Semra Paydas
Summary: This report presents a case of a 31-year-old man with jugular paraganglioma and multiple skeletal metastases. Chemotherapy and radiotherapy are feasible treatment methods for malignant paraganglioma with multiple distant metastases.
CURRENT MEDICAL IMAGING
(2022)
Article
Oncology
Tugba Basoglu, Abdullah Sakin, Cihan Erol, Ercan Ozden, Devrim cabuk, Ebru Cilbir, Deniz Tataroglu ozyukseler, Murat Ayhan, Mehmet Ali Sendur, Mutlu Dogan, Berna Oksuzoglu, Melek Karakurt Eryilmaz, Ozlem Er, Elif Senocak Tasci, Neslihan Ozyurt, Ozgecan Dulgar, Mirac Ozen, Ilhan Hacibekiroglu, Irem Oner, Esma Turkmen Bekmez, Hasan Cagri Yildirim, Suayib Yalcin, Semra Paydas, Emre Yekeduz, Asude Aksoy, Melike Ozcelik, Abdilkerim Oyman, Elvina Almuradova, Bulent Karabulut, Nazan Demir, Murat Dincer, Nuriye Ozdemir, Dilek Erdem, Naziye Ak, Ali Inal, Derya Kivrak Salim, Gulhan Ipek Deniz, Teoman Sakalar, Ahmet Gulmez, Turgut Kacan, Ozlem Ozdemir, Ozkan Alan, Caglar Unal, Yusuf Karakas, Serdar Turhal, Perran Fulden Yumuk
Summary: This study aimed to compare the efficacy and toxicity profile of different chemotherapy regimens in locally advanced GC and GEJ cancer patients in Turkey. The FLOT regimen showed higher rates of pathological complete remission and resection, but also higher chemotherapy-related toxicity. Longer follow-up period is needed to validate the results.
JOURNAL OF CHEMOTHERAPY
(2023)
Editorial Material
Hematology
Ertugrul Bayram, Umur Anil Pehlivan, David C. Fajgenbaum, Semra Paydas
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Ertugrul Bayram, Tugba Toyran, Semra Paydas
Summary: This article discusses a rare case of DRESS syndrome following treatment with Gemcitabine. The case report describes the patient's symptoms and treatment process, and ultimately concludes with a diagnosis of Gemcitabine-associated DRESS syndrome due to the lack of literature mentioning such a relationship.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Letter
Medicine, General & Internal
Merve Inceman, Umur Anil Pehlivan, Tugba Toyran, Recep Ozdek, Semra Paydas
CUKUROVA MEDICAL JOURNAL
(2023)
Article
Medicine, General & Internal
Tugba Toyran, Kivilcim Eren Erdogan, Emine Kilic Bagir, Arbil Acikalin, Merve Aksin, Semra Paydas, Burak Mete, Seyda Erdogan
Summary: This study aimed to compare clinicopathological features and evaluate the frequency of MSI, as well as survival rates in patients with MSI and MSS colorectal carcinomas. The results showed that MSI tumors were associated with younger age, early stage, right-side localization, lower lymph node metastasis rate, presence of mucinous component, and TILs response. Evaluating TILs, tumor budding score, and MSI can help improve the assessment of survival in these patients.
CUKUROVA MEDICAL JOURNAL
(2023)
Article
Medicine, General & Internal
Yegana Sadigova, Sevtap Seyfettinoglu, Umran Kucukgoz Gulec, Ghanim Khatib, Ahmet Bares Guzel, Derya Gumurdulu, Semra Paydas, Mehmet Ali Vardar
Summary: This study aimed to investigate the prognosis and survival rates of patients with malignant ovarian germ cell tumors, which are rare and significant. Analysis of clinicopathological records of 115 patients revealed that young, early-stage, and adequately operated patients had a good prognosis. For patients of reproductive age, fertility-sparing surgical approaches should be considered a good option.
CUKUROVA MEDICAL JOURNAL
(2023)
Article
Oncology
Ertugrul Bayram, Turgay Demir, Omer Kaya, Semra Paydas
Summary: This article reports a case of tetraplegia in a breast cancer patient caused by the use of vinorelbine. The drug was found to be responsible for the acute weakness and treatment was stopped. Although rare, cases of severe peripheral neuropathy following the use of vinorelbine have been reported.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Medicine, General & Internal
Abdullah Evren Yetisir, Semra Paydas, Mahmut Buyuksimsek, Ali Ogul, Oezge Yaprak, Suzan Zorludemir, Melek Ergin, Irem Kolsuz, Mehmet Mutlu Kidi
Summary: This study aimed to investigate the relationship between enhancer of zeste homolog 2 and mucin 1 expressions and pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. The results showed that patients with enhancer of zeste homolog 2 expression had higher rates of pathological complete response, while mucin 1 expression was not associated with pathological complete response.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
(2023)
Review
Oncology
Semra Paydas
Summary: Gestational trophoblastic neoplasias (GTNs) are chemosensitive disorders, but some individuals with chemoresistant diseases require innovative medications. Immunotherapy using immune checkpoint inhibitors (ICIs) is a critical component for managing drug-resistant GTN due to high PD-1 expression and paternal genetic inheritance. However, further multicenter studies are needed to identify prognostic markers due to the rarity of GTNs and limited literature data.
Article
Oncology
Semra Paydas, Ilhan Tuncer, Ahmet Baris Guzel, Cem Kaan Parsak, Ise Burak Guney
Summary: Sarcoid-like reaction, observed in cases treated with checkpoint inhibitors, can mimic disease progression in imaging, particularly PET/CT.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
(2022)
